Clinical Trial Update: Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating olaparib with or without cediranib or chemotherapy in platinum-resistant ovarian cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Cediranib (Cediranib)
• Olaparib (Olaparib)

Snippet

Sponsor: University of Oxford | Conditions: Ovarian Cancer | Phase 2 | Status: COMPLETED